Total trials
126
Active
21
Phase 3
1
Total enrollment
10,618
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| ganirelix acetate | — | — | — | — | — | 1 | |
| Estradiol | — | — | — | — | — | 1 | |
| Estrogen | — | — | — | — | — | 1 | |
| Furosemide | — | — | — | — | — | 1 |
Next readouts
- 2026-09-01
- 2026-10-31
- 2028-01-01
- 2030-06-01
Top conditions
- Stroke7
- Cardiovascular Risk Factor6
- Parkinson Disease5
- Hypertension5
- Aging5
- Physical Activity4
- Blood Pressure4
- Mild Cognitive Impairment4
Frequently asked questions about University of Delaware
- How many clinical trials does University of Delaware have on ClinicalTrials.gov?
- University of Delaware is listed as the lead sponsor on 126 clinical trials in ClinicalTrials.gov, 21 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Delaware's trials are in Phase 3?
- 1 of University of Delaware's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does University of Delaware focus on?
- University of Delaware's most-studied conditions on ClinicalTrials.gov are Stroke, Cardiovascular Risk Factor, Parkinson Disease, Hypertension, Aging.
- When are University of Delaware's next clinical trial readouts?
- University of Delaware has 4 upcoming primary-completion readouts tracked here; the soonest is “Impact of Estradiol on Endothelial Function in Peri-Menopausal Women”, expected around 2026-09-01.